News

Designation as an orphan drug, which is intended to facilitate product development, provides eligibility for a seven-year period of market exclusivity after approval, grants and tax credits for

In the exploratory clinical trial, Miraxion was used as adjunct therapy, with either selective serotonin reuptake inhibitors or tricyclics, in 115 patients with treatment-unresponsive depression. Although in the

This new compound, QRX-431, which QuatRx licensed from EndoChem, is designed to treat lipid abnormalities involving LDL-cholesterol and Lp(a), both recognized as risk factors for cardiovascular disease. The

The milestone is based on Genentech’s continued progress in preclinical development with an antibody-drug conjugate (ADC) utilizing Seattle Genetics’ technology. “We believe our ADC technology is contributing significantly

NCX 1020 is a nitric oxide (NO)-donating derivative of budesonide, a corticosteroid which is administered by inhalation for the long-term treatment of asthma, where it has been shown

Actelion and Merck formed an exclusive worldwide alliance in December 2003 to discover, develop and market new classes of renin inhibitors for patients suffering from cardio-renal diseases. Through

This randomized controlled study, known as the SMART trial, has enrolled 550 patients at 94 leading medical centers in the US, Canada, Europe and Australia. The trial is

In addition, the FDA has approved the enrollment in the study of patients with mastocytosis, an orphan disease involving new or abnormal cell growth, where Zyflo (zileuton tablets)

Under the agreement, VirtualScopics, a provider of imaging solutions utilizing biomarkers for pharmaceutical development, will provide analytical and other imaging services to Wyeth for use in the trial.